Lynch syndrome in the general population: low clinical utility of genomic screening for <i>PMS2</i> pathogenic variants
Kelly M. Schiabor Barrett(Helix (United States)), Alexandre Bolze(Helix (United States)), Catherine Hajek(Sanford Health), James T. Lu(Washington University in St. Louis), Joseph J. Grzymski(University of Nevada, Reno), Daniel P. Judge(Medical University of South Carolina), C. Anwar A. Chahal(WellSpan Health), Elizabeth T. Cirulli(Duke University), William Lee(Drexel University), Douglas A. Olson(HealthPartners), Christopher N. Chapman(St. Luke's University Health Network), Douglas Stoller(University of Nebraska Medical Center), Jeremy Cauwels(Sanford Health), Kate D. Lynch(Royal Adelaide Hospital)
Cited by 0
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k